Secukinumab Safety Profile in Children Aged 10 Years and Older
Secukinumab is FDA-approved and demonstrates a favorable long-term safety profile in children aged 6 years and older, with the most common adverse effects being nasopharyngitis, headache, and injection site reactions, while maintaining vigilance for increased infection risk. 1
FDA-Approved Pediatric Indications and Safety Data
The FDA label confirms secukinumab (Cosentyx) is approved for:
- Pediatric plaque psoriasis: Ages 6 years and older 1
- Juvenile psoriatic arthritis: Ages 2 years and older (≥15 kg body weight) 1
- Enthesitis-related arthritis: Ages 4 years and older (≥15 kg body weight) 1
This means a 10-year-old child falls well within the approved age range for multiple indications.
Most Recent Long-Term Safety Evidence (2026)
The highest quality recent evidence comes from a 236-week (4.5 years) Phase 3 extension study in pediatric patients with severe plaque psoriasis 2. This represents the longest follow-up data available for pediatric secukinumab use.
Key adverse events through 236 weeks (exposure-adjusted incidence rates per 100 patient-years):
- Nasopharyngitis: 13.9 (most common) 2
- Headache: 5.8 2
- Tonsillitis: 4.7 2
- Candida infections: Reported in only 3 patients over the entire study period 2
Infection Risk Monitoring
The major safety concern with biologics in children is injection site reactions and increased infection risk 3. The 2020 AAD-NPF guidelines specifically recommend monitoring pediatric patients for infection risk when using biologics 3.
However, the long-term data is reassuring:
- No serious opportunistic infections reported in the 236-week study 2
- Safety profile remained consistent with no new signals emerging over nearly 5 years of treatment 2
- Candida infections were rare (3 cases total) 2
Additional Safety Considerations from Recent Evidence
Generalized Pustular Psoriasis Data (2024-2025)
Real-world pediatric GPP studies show:
- No serious adverse events reported in children aged 0-12 years 4
- Adverse event rate approximately 17% across multiple studies 5
- Rapid onset of action with high safety profile 5
Two-Year Safety Data (2023)
The 104-week study (~320 patient-years of exposure) confirmed:
- Safety profile consistent with established adult data 6
- No unexpected safety signals 6
- Favorable tolerability maintained throughout 2 years 6
Practical Safety Monitoring Algorithm
For a 10-year-old starting secukinumab:
Baseline screening:
- Tuberculosis testing (though secukinumab does not significantly increase TB risk) 7
- Active infection assessment
- Vaccination status review
During treatment, monitor for:
- Upper respiratory infections (most common)
- Injection site reactions (major risk per guidelines) 3
- Candida infections (rare but reported)
- Headache
No routine laboratory monitoring required beyond standard clinical assessment, unlike traditional immunosuppressants
Important Caveats
- The FDA label notes that latex sensitivity should be considered, as the removable cap of certain formulations contains natural rubber latex 1
- Pregnancy monitoring becomes relevant as pediatric patients approach reproductive age (though not applicable to most 10-year-olds) 1
- Unlike traditional immunosuppressants (methotrexate, cyclosporine), secukinumab does not require intensive laboratory monitoring for hepatotoxicity or nephrotoxicity
Comparative Safety Context
The guidelines note that fumaric acid esters showed much higher adverse event rates (68% with discontinuation) compared to biologics in pediatric psoriasis 3. Secukinumab's safety profile is substantially more favorable, with most adverse events being mild and manageable upper respiratory infections.